In 2018, at a pediatric clinic in Manchester, UK, the recurring fever of 2-year-old Amelia gripped the entire medical team. This doll-like girl with curly eyelashes showed persistently low neutrophils (below 500/μL) in blood tests, while fat globules floating in her stool glowed like warning lights under the microscope. When "compound heterozygous mutation of SBDS gene" appeared on the genetic test report, her parents heard this seven-word medical term for the first time—Shwachman-Diamond Syndrome (SDS). This moment not only changed the trajectory of a family's fate but also reflected the half-century exploration journey of the global medical community.
At Boston Children's Hospital in 1964, Harry Shwachman and Louis Diamond, like modern medical Sherlock Holmes, meticulously analyzed 67 cases of children with "steatorrhea with neutropenia". They subtly observed: these children's pancreatic sections showed unique "snowflake-like" acinar atrophy under the microscope, and the metaphyseal dysplasia on bone X-rays resembled etched ivory. This landmark report published in Pediatrics sketched the first clinical portrait of this disease later named SDS.
As the Human Genome Project progressed vigorously, a 2003 cover article in Nature Genetics struck like lightning—a multinational research team identified the SBDS gene on the long arm of chromosome 7. This tiny 1.6kb gene encodes a protein that controls the precision valve of ribosome biogenesis. Scientists discovered that 97% of SDS patients carry two specific mutation sites in the SBDS gene (c.183_184TA>CT and c.258+2T>C). This molecular disaster caused by genetic conversion errors explains why hematopoietic stem cells and pancreatic exocrine cells are the first to be affected in patients.
In healthy cells, the SBDS protein acts like a precise assembly line inspector:
• Assists in the maturation of the 60S ribosomal subunit, ensuring the perfect assembly of mRNA translation machinery
• Participates in the formation of stress granules, activating emergency protocols when cells are attacked
• Regulates actin cytoskeleton dynamics, maintaining the bone marrow homing ability of hematopoietic stem cells
When SBDS function is deficient, hematopoietic stem cells are like ships without GPS navigation, losing their way in the bone marrow microenvironment, eventually leading to progressive bone marrow failure.
• Pancreas: Acinar cell apoptosis reduces lipase secretion to 1% of normal levels, with undigested fat forming "cream-like stools" in the intestines
• Skeleton: Impaired differentiation of growth plate chondrocytes results in height below the 3rd percentile, with 30% of patients developing "rocker-bottom feet" deformity
• Immune system: Neutrophil chemotaxis defects can turn ordinary infections into sepsis storms
A groundbreaking 2021 study in Blood revealed a deeper mechanism: SBDS deficiency activates the p53-dependent cellular senescence pathway, explaining why the risk of bone marrow failure in SDS patients increases exponentially with age.
From traditional 72-hour fecal fat quantification to next-generation sequencing (NGS) achieving a 98% detection rate, the diagnostic time has shortened from an average of 4.2 years to 11 months. The "SDS Risk Scoring System" developed by the National Center for Child Health and Development in Japan enables early warning through three dimensions: absolute neutrophil count, trypsinogen level, and skeletal abnormalities.
• Pancreatic battlefield: Enzyme replacement therapy improves children's weight z-score from -2.5 to -1.3 (data from European multi-center studies)
• Hematological battlefield: A transplant risk model established by Canadian researchers shows that the 5-year survival rate of HLA-matched donor transplantation reaches 78%
• Genetic battlefield: The 2022 CRISPR/Cas9 repair experiment at Boston Children's Hospital successfully restored neutrophil differentiation ability in patient-derived iPSCs
The "RESCUE-SDS" project led by the US NIH is evaluating the feasibility of delivering corrected SBDS genes via adeno-associated virus (AAV) vectors. Base editing technology shows unique advantages—it can precisely repair the c.183TA>CT mutation without cutting DNA double strands, with preclinical studies showing an editing efficiency of 41%.
The "artificial thymic microenvironment" technology pioneered by a Cambridge team in the UK increases transplantation efficiency by 3 times after co-culturing patient hematopoietic stem cells with engineered stromal cells. Kyoto University in Japan uses mRNA reprogramming technology to directly convert skin fibroblasts into fully functional pancreatic acinar cells.
The global SDS registry platform built by the European Commission for Rare Diseases has integrated complete life cycle data of 586 patients from 37 countries. Machine learning models analyzing this data have successfully predicted the progression rate of bone marrow failure with 89% accuracy.
At an SDS children's summer camp in São Paulo, Brazil, 13-year-old Carlos proudly displayed his "Pancreatic Enzyme Assistant" app—this program that automatically calculates enzyme doses based on food photos won an international youth technology competition gold medal. Across the ocean, 25-year-old Lindsay, the first SDS patient to receive a new STAT3 inhibitor, has maintained a stable neutrophil count of 1500/μL for 18 months.
As Professor Marco Zecca, President of the International SDS Alliance, stated: "We stand at a historical turning point from symptomatic treatment to radical therapy." When gene therapy, artificial intelligence, and global collaborative networks refract the light of hope, this once suffocating genetic maze for countless families will finally be fully illuminated by the brilliance of human wisdom.
Epilogue: Starting from that clinic at Boston Children's Hospital, through six decades, the global medical community's understanding of SDS has evolved from a vague clinical syndrome to a clear molecular portrait. In this cross-time medical relay, every interpretation of base pairs, every successful transplantation, and every international data sharing is rewriting the fate script of SDS patients. When future history books open this page, they will surely remember this as one of the most exciting battles in the era of precision medicine—humanity using technological power to carve out an oasis of life in the genetic desert.
EN
CN